Mounjaro in Philadelphia, PA — pricing, telehealth, coverage

1. Insurance + retail pharmacy

If you have commercial insurance or Medicare that includes Mounjaro on formulary, your physician or telehealth provider can send a prescription to any major retail pharmacy in Philadelphia: CVS, Walgreens, Walmart, Costco, or grocery-store pharmacy counters. Copays depend on your plan's tier placement and any prior-authorization requirements. For type 2 diabetes, prior authorization typically requires documented T2D diagnosis (ICD-10 codes, A1c results) and often a metformin trial.

2. Telehealth providers serving Pennsylvania

Multiple telehealth providers are licensed to prescribe Mounjaro to PA residents. These services typically include the medical consultation, ongoing follow-up, and a prescription sent to a pharmacy of your choice or to an affiliated mail-order pharmacy. See our provider directory to filter by PA-licensed services.

3. Manufacturer savings programs

Eli Lilly operates LillyDirect, a direct-pay program with uniform national pricing for eligible self-pay patients of Mounjaro. LillyDirect pricing applies in Philadelphia the same as anywhere else in the US. Eligibility criteria typically include US residency, prescription for an FDA-approved indication, and proof of self-pay status (no insurance billing for this fill).

4. Compounded tirzepatide (if available)

Compounded tirzepatide is offered by some telehealth providers serving Pennsylvania. Compounded GLP-1 medications are NOT FDA-approved as finished products. FDA removed both semaglutide and tirzepatide from the official drug shortage list in 2024-2025, which constrains commercial-scale compounding under FDCA §503B; patient-specific compounding under §503A remains permitted in narrow circumstances. See our compounded GLP-1 buyer guide for current safety considerations.

State-level coverage patterns for Mounjaro in Pennsylvania:

• Medicaid: Pennsylvania Medical Assistance (HealthChoices) generally covers Mounjaro for FDA-approved type 2 diabetes with prior authorization. T2D coverage is typically broader than weight-loss coverage.
• Medicare: Medicare Part D does not cover GLP-1 medications prescribed for weight loss (statutory exclusion under SSA §1860D-2(e)(2)(A)). T2D coverage of Ozempic, Mounjaro, and Rybelsus is available with prior auth. Wegovy received a Medicare Part D coverage path for adults with established cardiovascular disease and overweight/obesity following the SELECT trial label expansion.
• Commercial: Coverage varies dramatically by employer plan design, particularly for weight-loss indications. Many self-funded ASO employer plans exclude anti-obesity medications. Verify with your specific plan.

For a structured state-by-state coverage breakdown, see our pricing-by-state map and payer-coverage guides.